Seulki Lee

Company: D&D Pharmatech

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Discussing the Future Indications of GLP-1-Based Therapeutics – Promises & Challenges 2:30 pm

Advancing the reach of GLP-1-based treatments into other therapeutic areas, particularly Alzheimer’s and Parkinson’s disease Exploring the scientific validity of the latest treatment frontiers with GLP-1s to understand the potential in these areas Considering the commercial possibilities of these new therapeutic area markets to grasp the scope of opportunityRead more

day: Conference Day One

Advancing DD01, a Ratio Optimized GLP-1/GCG Agonist for Rapid Liver Fat Reduction Regardless of Body Weight Loss & Exploring Novel Approaches for Oral Peptide Delivery 11:30 am

Focusing on phase 1 clinical data of GLP-1/GCG treatment in obese/overweight patients with T2D and/or NASH Understanding the significance of rapid liver fat reduction in NAFLD/NASH patients with GLP-1/GCG dual agonists Introducing novel methods to orally deliver peptide drugs, improving ease of administrationRead more

day: Conference Day One